Miriam Méndez del Villar

Dr. Miriam Méndez del Villar

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
WTWalter Ángel Trujillo-Rangel
Walter Ángel Trujillo-Rangel
LGLeonel García-Valdés
Leonel García-Valdés
Miriam Méndez del VillarMiriam Méndez del Villar
Miriam Méndez del Villar
RCRolando Castañeda
Rolando Castañeda
STSylvia Elena Totsuka
Sylvia Elena Totsuka
LBLeonel García Benavides
Leonel García Benavides
Ischemia‐reperfusion (I‐R) injury is damage caused by restoring blood flow into ischemic tissues or organs. This complex and characteristic lesion accelerates cell death induced by signaling pathways such as apoptosis, necrosis, and even ferroptosis. In addition to the direct association between I‐R and the release of reactive oxygen species and reactive nitrogen species, it is involved in developing mitochondrial oxidative damage. Thus, its mechanism plays a critical role via reactive species scavenging, calcium overload modulation, electron transport chain blocking, mitochondrial permeability transition pore activation, or noncoding RNA transcription. Other receptors and molecules reduce tissue and organ damage caused by this pathology and other related diseases. These molecular targets have been gradually discovered and have essential roles in I‐R resolution. Therefore, the current study is aimed at highlighting the importance of these discoveries. In this review, we inquire about the oxidative damage receptors that are relevant to reducing the damage induced by oxidative stress associated with I‐R. Several complications on surgical techniques and pathology interventions do not mitigate the damage caused by I‐R. Nevertheless, these therapies developed using alternative targets could work as coadjuvants in tissue transplants or I‐R‐related pathologies

1 June 2018 in Journal of Medicinal Food
Verified
Journal Article
Closed access
Miriam Méndez del VillarMiriam Méndez del Villar
Miriam Méndez del Villar
MGManuel González-Ortiz
Manuel González-Ortiz
EMEsperanza Martínez-Abundis
Esperanza Martínez-Abundis
KPKarina G. Pérez-Rubio
Karina G. Pérez-Rubio
MCMarisol Cortez-Navarrete
Marisol Cortez-Navarrete
The aim of this study was to evaluate the effect of Irvingia gabonensis on metabolic syndrome (MetS), insulin sensitivity, and insulin secretion. A randomized, double-blind, placebo-controlled clinical trial was performed in 24 patients with MetS in accordance with the International Diabetes Federation criteria. Twelve patients received I. gabonensis (150 mg) twice a day during 90 days, and 12 patients received placebo. Glucose and insulin concentrations were measured during a 2-h oral glucose tolerance test. Also, lipid profile, creatinine, uric acid, and hepatic enzymes were determined. The area under the curve (AUC) of glucose and insulin, total insulin secretion, first phase of insulin secretion, and insulin sensitivity were calculated. Data were tested using non-parametric tests. The Ethics Committee approved the protocol. After I. gabonensis administration, significant decreases in waist circumference (WC) (94.0 ± 8.0 vs. 91.0 ± 8.2 cm, P < .01), glucose 90' (10.0 ± 2.5 vs. 8.6 ± 2.7 mmol/L, P < .05), glucose 120' (8.8 ± 2.4 vs. 7.6 ± 2.7 mmol/L, P < .05), triglycerides (2.5 ± 1.2 vs. 2.0 ± 1.1 mmol/L, P < .05), very low-density lipoproteins (VLDL) (0.5 ± 0.2 vs. 0.4 ± 0.2 mmol/L, P < .05), and AUC of glucose (694 ± 142 vs. 629 ± 172 mmol/L/min, P < .05) were found. Seven patients (58.3%) of the I. gabonensis group showed remission of MetS and two patients (16.7%) of the placebo group (P = .045). I. gabonensis lead to remission of MetS in 58.3% of the patients and significantly decreased WC, glucose 90', glucose 120', triglycerides, VLDL, and AUC of glucose.

Verified
Journal Article
Open access
PDF file
EGEsteban Alejandro Gomez-Gaitan
Esteban Alejandro Gomez-Gaitan
YOYESSICA ELEANET GARCIA ORTEGA
YESSICA ELEANET GARCIA ORTEGA
ASAna Miriam Saldaña-Cruz
Ana Miriam Saldaña-Cruz
BCBetsabe Contreras-Haro
Betsabe Contreras-Haro
JGJorge I. Gamez-Nava
Jorge I. Gamez-Nava
MMMiguel Angel Macias
Miguel Angel Macias
Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by genetic factors such as genetic variants. Therefore, our study aimed to investigate the association of the HLA-DRB1*0403 genetic variant and therapeutic response to DMTs in MS. We included 105 patients with MS diagnosis. No evidence of disease activity based on the absence of clinical relapse, disability progression or radiological activity (NEDA-3) was used to classify the therapeutic response. Patients were classified as follows: (a) controls: patients who achieved NEDA-3; (b) cases: patients who did not achieve NEDA-3. DNA was extracted from peripheral blood leukocytes. HLA-DRB1*0403 genetic variant was analyzed by quantitative polymerase chain reaction (qPCR) using TaqMan probes. NEDA-3 was achieved in 86.7% of MS patients treated with DMTs. Genotype frequencies were GG 50.5%, GA 34.3%, and AA 15.2%. No differences were observed in the genetic variant AA between patients who achieved NEDA-3 versus patients who did not achieve NEDA-3 (48.7% vs. 43.1%, p = 0.6). We concluded that in Mexican patients with MS, HLA-DRB1*0403 was not associated with the therapeutic response to DMTs.

19 July 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Mariana Chávez-TostadoMariana Chávez-Tostado
Mariana Chávez-Tostado
KTKarla Veronica Chavez Tostado
Karla Veronica Chavez Tostado
GCGabino Cervantes-Guevara
Gabino Cervantes-Guevara
GCGuillermo A. Cervantes-Cardona
Guillermo A. Cervantes-Cardona
DHDiana Mercedes Hernandez-Corona
Diana Mercedes Hernandez-Corona
AGAlejandro González-Ojeda
Alejandro González-Ojeda
Background: Breastfeeding is a characteristic process of mammals that ensures delivery of an adequate nutritional supply to infants. It is the gold standard food source during an infant’s first months of life. Since the onset of the COVID-19 pandemic in 2020, people in quarantine have experienced a wide range of feelings, which may make isolation challenging in terms of maternal health. This study focused on the prevalence of breastfeeding practices and postpartum depression (PPD) among Mexican women during the COVID-19 pandemic. Materials and Methods: This cross-sectional study included 586 postpartum women who completed an online survey 4−8 weeks after delivery from April to December 2020 in Guadalajara, Mexico. The aim was to identify potentially depressed mothers according to the Edinburgh Postnatal Depression Scale (EPDS) and describe their breastfeeding practices. Results: The mean maternal age was 30.4 ± 4.6 years, the mean EPDS score was 9.6 ± 5.0, and the PPD prevalence according EPDS scores was 27.1%. Exclusive breastfeeding (EBF) was reported by 32.3% of mothers in the first 48 h and by 70.3% of mothers 48 h after delivery. EBF was associated with a lower prevalence of PPD during the first 48 h (p = 0.015) and after the first 48 h (p = 0.001) after delivery. Skin-to-skin contact (SSC) was reported by 385 (65.7%) mothers. PPD was less frequent in mothers practicing SSC (20.3%) than it was in those not practicing SSC (40.3%) (p = 0.001). A higher percentage of mothers practiced SSC breastfed (66.9%) and used EBF (150, 79.4%) (p = 0.012 and 0.001, respectively). Conclusions: Results suggest that the pandemic emergency and restrictions imposed on the population significantly affected the well-being of mothers after birth, and that these effects may have posed risks to the mental health and emotional stability of postpartum mothers. Therefore, encouraging BF or EBF and SSC may improve or limit depressive symptoms in postpartum mothers.

26 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GCGabino Cervantes-Guevara
Gabino Cervantes-Guevara
BVBlanca Ernestina Vázquez-López
Blanca Ernestina Vázquez-López
LMLisset Citlalic Magaña
Lisset Citlalic Magaña
FSFernanda Monserrat Rendón Serrano
Fernanda Monserrat Rendón Serrano
CFClotilde Fuentes-Orozco
Clotilde Fuentes-Orozco
Mariana Chávez-TostadoMariana Chávez-Tostado
Mariana Chávez-Tostado
Introduction: Malnutrition is a critical issue among cancer patients, leading to adverse clinical outcomes, including increased treatment toxicity, reduced physical function, and decreased survival. Nutritional screening is essential to identify patients at risk and provide timely interventions. Objectives: This study aimed to assess the effectiveness of various nutritional screening tools in identifying the risk of malnutrition and obesity in Mexican cancer outpatients. Methods: A cross-sectional study was conducted with 396 adult cancer outpatients at a public hospital in Mexico. Nutritional risk was evaluated using NRS-2002, MUST, MST, NUTRISCORE, and PG-SGA, while malnutrition was assessed using GLIM criteria and PG-SGA. Anthropometric and demographic data were collected. Sensitivity, specificity, and kappa coefficients were calculated to determine the performance of the screening tools. Results: Nutritional risk was identified in 22.7–26.5% of patients, with the highest agreement observed between MUST and PG-SGA (k = 0.64). Malnutrition prevalence was higher using GLIM criteria (37.4%) compared to PG-SGA (25.8%, p < 0.001). Overweight and obesity affected 37.1% and 23.5% of patients, respectively. Low BMI and reduced HGS were strongly associated with nutritional risk and malnutrition (p < 0.001). Conclusions: MUST and PG-SGA are reliable tools for nutritional screening in cancer outpatients, while GLIM criteria detect a higher prevalence of malnutrition than PG-SGA. The high rates of overweight and obesity highlight the complex nutritional challenges in this population, emphasizing the need for tailored nutritional assessments and interventions.

11 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RGRoberto Carlos Rosales Gómez
Roberto Carlos Rosales Gómez
BMBeatriz Teresita Martin Marquez
Beatriz Teresita Martin Marquez
ACAlvaro Jovanny Tovar Cuevas
Alvaro Jovanny Tovar Cuevas
OCOmar Cardenas-Saenz
Omar Cardenas-Saenz
POPatricia Orozco-Puga
Patricia Orozco-Puga
FCFernanda-Isadora Corona-Meraz
Fernanda-Isadora Corona-Meraz
Background: Migraine is a disabling neurological disorder where the release of neuropeptides and a local and systemic proinflammatory state prevail. MicroRNAs (miRs) are epigenetic regulators that control the expression of genes involved in inflammation, neovascularization, and pain-related processes. Cytokines mediate the inflammatory state, while miRs can modulate their expression. Methods: This is an analytical and observational study in which subjects with a diagnosis of chronic and episodic migraine and healthy controls were recruited, and the migraine patients were classified by episodic or chronic migraine, as well as with or without aura. Cytokines were measured using the ELISA technique, and the microRNAs hsa-miR-197-3p, hsa-miR-101-3p, and hsa-miR-143-3p were evaluated using qPCR methodology. We also utilized bioinformatic tools, such as miRBase, TargetScan, miRNet, and miRPath, to analyze the interactions and pathways involved. Results: Our findings revealed that hsa-miR-197-3p is elevated in patients without aura (29.91 ± 11.14 with aura vs. 81.10 ± 53.85 without aura, RU; p = 0.021), whereas hsa-miR-143-3p is elevated in episodic migraine (0.0639 ± 0.0227 in EM vs. 0.0308 ± 0.0174, RU p = 0.011). Furthermore, we found higher levels of IL-17 (9.46 ± 1.06 in CM vs. 7.61 ± 2.12 in EM, p = 0.030), IL-6 (4.95 ± 2.84 in CM vs. 1.52 ± 0.98 non-migraine subjects, p = 0.016), and TNFα in chronic migraine patients (0.46 ± 0.24 in CM vs. 0.20 ± 0.05 in non-migraine, p = 0.011 and vs. 0.20 ± 0.13 in EM, p = 0.016). Conclusions: Inflammation is present in migraine regardless of the clinical characteristics of the patients, although it may be accentuated in chronic migraine. Our preliminary findings suggest a potential role for peripheral inflammatory markers, including specific microRNAs (miR-197, miR-101, and miR-143) and cytokines (TNF-α, IL-6, and IL-17A), in the pathophysiology of migraine. These results, although limited by sample size and cross-sectional design, highlight molecular pathways that warrant further investigation.